Coagulation factor XIa (FXIa) (FXIa)

Coagulation factor XIa (FXIa) is a key serine protease in the intrinsic pathway of the blood coagulation cascade, responsible for activating factor IX [1]. In cynomolgus monkeys (Macaca fascicularis), this enzyme serves as a vital preclinical model for human coagulation due to its high structural and functional similarity to the human ortholog [2]. FXIa is an attractive therapeutic target because its inhibition effectively prevents pathological thrombosis while maintaining relatively normal hemostasis, thereby offering a wider safety margin regarding bleeding compared to traditional anticoagulants [3]. Drugs targeting FXIa, including small molecules like Milvexian and monoclonal antibodies like Abelacimab, are being developed to treat conditions such as venous thromboembolism and stroke [4]. Preclinical studies in cynomolgus monkeys are essential for evaluating the pharmacokinetics and pharmacodynamics of these novel inhibitors before human clinical trials [5]. This target is particularly relevant for assessing the antithrombotic without pro-bleeding hypothesis in a non-human primate model [6].

Other names

Factor XIaPlasma thromboplastin antecedentFXIF11Activated coagulation factor XICynomolgus monkey coagulation factor XIa

Inhibition of the enzymatic activity of factor XIa to prevent thrombus formation by blocking the activation of factor IX.